• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Stories

Living with dengue: ‘It’s everywhere and there’s nothing we can do about it.’

Home > Stories

Living with dengue: ‘It’s everywhere and there’s nothing we can do about it.’

26 Jan 2022
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Dengue is one of the top ten threats to public health worldwide. Dengue incidence has grown by 85% over the last 50 years. It continues to spread rapidly, fuelled by urbanization, population growth and climate change. Today, nearly 4 billion people in 129 countries are at risk of dengue infection.

To hear more about people’s experiences, we visited recovered dengue patients in the historic city of Malacca in Malaysia, living in the highest risk areas for dengue, known as ‘red zones’.

We met 31-year-old Ma Tan Jhii Lian (Jhii), who in 2020 was infected by dengue twice in just three months.

Woman standing in front of a car

The first time, she went to see a doctor with a fever of 40°C (104 °F), body aches, and weakness. When he found out where she lived, he immediately ordered a dengue test. The result was positive.

’I didn’t know what to expect, but I heard it could be quite serious. Because I have worked in hospitals, I have seen cases where dengue patients had to be admitted into the intensive care unit,’ Jhii said. She was sent home with medicines and instructions to rest, but as her fever got worse, Jhii found herself in and out of different hospitals.

Leaving her young baby was the most difficult aspect of the new mother’s ordeal. ‘The first time my daughter was just around six months old, and the worst thing is that she’s never been away from me before since her birth. We were so worried about who would take care of her and how long I would have to be in the ward.‘

‘I was stuck there with a high fever. I was shivering even with a jacket and four layers of blankets covering me. There’s no treatment, there’s only symptomatic treatment available right now. I couldn’t fight back, so I just endured the whole experience.’

Following her recovery, Jhii and her family took stringent preventative precautions. They covered all doors and windows with mosquito netting and avoided going out at peak mosquito biting times. But just three months later, she got infected again.

‘After you  get infected with dengue, you don’t know what will happen. How your body reacts is based on luck and other factors. I got it again three months after the first infection. Who can be so unlucky?’

While the first infection had caused symptoms of high fever, lethargy, and muscle aches, this time she had severe abdominal cramps and diarrhoea. ’The second time, I couldn’t even take in any food or even water. Just one sip made the cramp so bad. It was really painful.’

Because there is no specific treatment for dengue, once again the hospital could only give her supportive care. ‘They gave me anti-diarrhoea medication, paracetamol, and a drip, that’s all.‘

Because of the infections, Jhii told us ‘my milk supply halved after each infection and as a result, I only managed to breastfeed my daughter until she was ten months old.’

City of Malacca, Malaysia

Living in a dengue red zone puts Jhii at high risk. ’I’m still living in fear that I might contract the virus a third and fourth time. Every time they do the fogging, we know that there is a case, and it’s actually quite frequent in my neighbourhood.’

’I know that the more times you get dengue, the more serious it can get. So, of course I’m scared. The first time I just had a fever, but the second time my blood result was worrying. So, I’m scared of what will happen if I get it a third time.’ Jhi also particularly worries about her daughter. ’She’s so young. For me having been infected twice, there’s a very high risk of her getting it. I just can’t imagine a baby contracting dengue.’ 

’It’s everywhere and there’s nothing we can do about it. If we had a vaccine or medication to treat it, at least we would know there’s a solution.’

Across the world dengue causes immense individual suffering and puts enormous pressure on over-burdened health systems. In South-East Asia the incidence of dengue increased by 46% between 2015 and 2019, mostly affecting children under the age of 15. Severe dengue is a leading cause of hospitalization and death in many countries. In Malaysia, the last major outbreak in 2019, as an epidemic swept South-East Asia, saw a new record of 131,000 cases.

DNDi is partnering with dengue-endemic countries on a project that aims to find a safe, affordable, and effective treatment for dengue.

READ more about this partnership

Photo credit: Abang Amirrul Hadi – DNDi

Dengue Asia Malaysia

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By continuing to browse our website, you are agreeing to our use of cookies.CLOSECOOKIE POLICY